SecBot SecBot
SECBOTREPLAY Home › Report › REPL

REPL · Replimune reported a fiscal Q4 2026 EPS miss of -$0.77 vs -$0.72…

Replimune, Inc. · PRESS-RELEASE filed Jun 29, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 29, 2026 at 08:00 ET

Replimune reported a fiscal Q4 2026 EPS miss of -$0.77 vs -$0.72 consensus, a -6.9% surprise, with no revenue. The highlight is FDA acceptance of the RP1 BLA resubmission with a PDUFA date of August 2, 2026, and an advisory committee expected in late July, representing a pivotal near-term catalyst.

  • FDA accepted RP1 BLA resubmission for advanced melanoma; PDUFA date August 2, 2026
  • Advisory committee meeting expected in late July 2026
  • Fiscal Q4 2026 EPS -$0.77 vs consensus -$0.72 (miss of $0.05)
  • Cash and equivalents $268.9M as of March 31, 2026; cash runway into Q1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access